...
首页> 外文期刊>American Journal of Physiology >Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma
【24h】

Acid, basic, and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma

机译:酸性,碱性和中性肽酶在发色肾细胞癌和肿瘤细胞瘤中表现出不同的特征

获取原文
获取原文并翻译 | 示例

摘要

Renal cell carcinomas (RCCs) are neoplasias with high prevalence and mortality. We previously reported that several peptidases may be involved in the pathophysiology of clear cell renal cell carcinoma (CCRCC). Now, to gain insight into the reasons that lead the various RCC types to behave very differently with regard to aggressiveness and response to anti-cancer treatments, we analyzed subsets of chromophobe renal cell carcinoma (ChRCC), and renal oncocytoma (RO), a benign tumor; as well as different grades and stages of CCRCCs. Particulate APN, APB, and APA activities were decreased in both ChRCC and RO (tumor vs. nontumor tissues). Interestingly, activities were downregulatedin a tumor-type specific way and the intensities of the decreases were stronger in the benign tumor than in the malignant type. Moreover, when two key histopathological parameters for tumor prognosis (high vs. low stage and grade) were analyzed, increases of activity were also observed in several of these cell surface peptidases (APN, APB). Some soluble activities (APB, Asp-AP) were also downregulated in the RCCs. With respect to genetic expression, PSA and APN were in a positive correlation related to their activities in both ChRCC and RO; but not APB, Asp-AP, APA, and PGI. These results may suggest an involvement of several peptidases in the pathophysiology of renal cancer, since they presented different patterns of activity and expression in tumors with different behaviors.
机译:肾细胞癌(RCC)是具有高患病率和死亡率的肿瘤。我们之前曾报道过几种肽酶可能参与了透明细胞肾细胞癌(CCRCC)的病理生理。现在,为了深入了解导致各种RCC类型在侵略性和对抗癌治疗的反应方面表现出很大差异的原因,我们分析了发色性肾细胞癌(ChRCC)和肾癌细胞瘤(RO)的子集。良性肿瘤以及CCRCC的不同等级和阶段。在ChRCC和RO(肿瘤组织与非肿瘤组织)中,微粒APN,APB和APA活性均降低。有趣的是,以肿瘤类型特异性的方式下调了活性,并且良性肿瘤中的降低强度比恶性类型中的强。此外,当分析了两个用于肿瘤预后的关键组织病理学参数(高低分期和等级)时,在这些细胞表面肽酶中的一些(APN,APB)中也观察到了活性的增加。 RCC中的一些可溶性活性(APB,Asp-AP)也被下调。在基因表达方面,PSA和APN与其在ChRCC和RO中的活性呈正相关。但不是APB,Asp-AP,APA和PGI。这些结果可能表明几种肽酶参与了肾癌的病理生理,因为它们在具有不同行为的肿瘤中表现出不同的活性和表达模式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号